Peake Sandra L, Pierides John, Leppard Phillip I, Russ Graeme R
Transplant Immunology Laboratory, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Crit Care Med. 2002 Jan;30(1):171-81. doi: 10.1097/00003246-200201000-00025.
To investigate the efficacy of an anti-ovine interleukin-1beta monoclonal antibody to ameliorate pathophysiological derangements and improve survival in an ovine model of gram-negative septic shock.
Prospective, placebo-controlled, interventional study (24-hr study period).
University hospital animal research laboratory.
Ten awake, mature female sheep.
Seven milligrams per kilogram of intravenous anti-ovine interleukin-1beta immunoglobin G1 monoclonal antibody (anti-interleukin-1beta group, n = 5) or equivalent amount of protein (5% human albumin; control group, n = 5) was infused over 1 hr (time-zero minus 1 hr to time-zero) and followed by an intravenous LD100 live Escherichia coli infusion (time-zero to time-zero plus 1 hr). Normal saline, maintenance and boluses to maintain baseline filling pressures, and gentamicin, 3 mg/kg intravenous, at time-zero plus 2 and time-zero plus 13 hrs.
Hemodynamic and oxygen transport indexes as well as hematological, biochemical, cytokine (interleukin-1beta, tumor necrosis factor-alpha), and endotoxin measurements were performed at baseline (time-zero minus 1 hr), on completion of the monoclonal antibody/placebo (time-zero) and E. coli (time-zero plus 1 hr) infusions, and at multiple time points thereafter (time-zero plus 1.5 hrs to time-zero plus 24 hrs). Baseline data were not different between the treatment groups. From time-zero plus 1.5 hrs onward, in the anti-interleukin-1beta group, there was a sustained increase in mean arterial pressure, decreased peripheral vasodilation, and an attenuated metabolic acidosis, relative to the control group (p < or = .01, repeated-measures analysis of variance). Predicted percentage increases in mean arterial pressure and systemic vascular resistance index relative to the control group were 35% and 40%, respectively. Resuscitation fluid requirements were also decreased: anti-interleukin-1beta group, 4.1 +/- 2.9 mL x kg(-1) x hr(-1); control group, 10.6 +/- 1.8 mL x kg(-1) x hr(-1) (p < or = .01, Student's t-test). Survival was not different (anti-interleukin-1beta group, 40%; control group, 0%; p > .01, log-rank test).
Adjunctive therapy with anti-ovine interleukin-1beta monoclonal antibody in ovine gram-negative septic shock was associated with improved hemodynamic performance. However, the beneficial effects were incomplete and survival was not significantly improved.
在革兰氏阴性菌感染性休克绵羊模型中,研究抗绵羊白细胞介素-1β单克隆抗体改善病理生理紊乱及提高生存率的疗效。
前瞻性、安慰剂对照、干预性研究(研究期24小时)。
大学医院动物研究实验室。
10只清醒的成年雌性绵羊。
每千克静脉注射7毫克抗绵羊白细胞介素-1β免疫球蛋白G1单克隆抗体(抗白细胞介素-1β组,n = 5)或等量蛋白质(5%人白蛋白;对照组,n = 5),于1小时内输注(从零时减去1小时至零时),随后静脉注射致死剂量100的活大肠杆菌(从零时到零时加1小时)。在零时加2小时和零时加13小时静脉注射生理盐水、维持量和冲击量以维持基线充盈压,以及3毫克/千克的庆大霉素。
在基线(零时减去1小时)、单克隆抗体/安慰剂输注结束时(零时)和大肠杆菌输注结束时(零时加1小时)以及此后的多个时间点(零时加1.5小时至零时加24小时)进行血流动力学和氧输送指标以及血液学、生化、细胞因子(白细胞介素-1β、肿瘤坏死因子-α)和内毒素测量。治疗组间基线数据无差异。从零时加1.5小时起,与对照组相比,抗白细胞介素-1β组平均动脉压持续升高,外周血管扩张减轻,代谢性酸中毒减轻(p≤0.01,重复测量方差分析)。相对于对照组,平均动脉压和全身血管阻力指数的预测百分比增加分别为35%和40%。复苏液体需求量也减少:抗白细胞介素-1β组,4.1±2.9毫升·千克⁻¹·小时⁻¹;对照组,10.6±1.8毫升·千克⁻¹·小时⁻¹(p≤0.01,学生t检验)。生存率无差异(抗白细胞介素-1β组,40%;对照组,0%;p>0.01,对数秩检验)。
在绵羊革兰氏阴性菌感染性休克中,抗绵羊白细胞介素-1β单克隆抗体辅助治疗可改善血流动力学表现。然而,有益效果不完全,生存率未显著提高。